Respiratory diseases-including chronic obstructive pulmonary disease (COPD), asthma, and pulmonary fibrosis-are major threats to public health worldwide. With rising environmental pollution, aging populations, and increasing chronic disease rates, the need for accurate preclinical models and innovative treatment research has never been more urgent.
In response to these challenges, Prisys Biotech has established a robust, comprehensive research platform dedicated to advancing the study and treatment of respiratory diseases. Specializing in non-human primate (NHP) disease models and advanced drug delivery technologies, Prisys stands at the forefront of translational respiratory research.
Focus on COPD Models: Realistic Simulation for Drug Efficacy Evaluation
COPD is a chronic airway disease primarily triggered by long-term smoking and environmental exposure. Prisys's non-human primate COPD model is induced via cigarette smoke, mimicking the most common pathogenic mechanisms observed in human patients. This model accurately replicates critical symptoms such as airway inflammation, pulmonary dysfunction, and tissue remodeling-making it an ideal platform for preclinical testing and drug development.
With continuous advancements in model refinement and validation, Prisys provides a clinically relevant tool to support new therapies targeting COPD and chronic respiratory diseases.
Comprehensive Respiratory Disease Models: Scientifically Rigorous, Broadly Applicable
Beyond COPD, Prisys offers a full suite of respiratory disease models tailored for diverse research needs:
Asthma/Atopic Dermatitis Models: Induced by ovalbumin (OVA) or house dust mites to replicate allergic airway inflammation. Key features include:
- Immune sensitization and inhalation challenges mimicking human asthma progression.
- Hallmarks such as increased airway resistance, eosinophilic infiltration in lungs and bronchi, and elevated Th2 cytokines.
- Airway hyperresponsiveness reversible with fluticasone.
- Quantitative assessments through acetylcholine (ACh) PC50 testing.
- Bronchoalveolar lavage fluid (BALF) analysis, including IL-6, IL-8, IL-1β, TNF-α detection and cell counts.
- Lung function evaluations including forced vital capacity (FVC) and resistance (RL).
- Supports dual induction of asthma and atopic dermatitis.
Acute Lung Inflammation Models: Induced via LPS or chemical agents (e.g., diluted HCl) to create consistent neutrophilic inflammation, simulating acute lung injury or inhalation pneumonia.
Pulmonary Fibrosis Models: Designed to reflect chronic progressive interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF), facilitating in-depth mechanistic and therapeutic research.
Allergic Rhinitis & BSL-2 Pathogen Exposure Models: Enable exploration of immune responses and vaccine efficacy under controlled biosafety conditions.
Innovative Drug Delivery Systems: Targeted, Efficient, and Versatile
Understanding that drug efficacy heavily depends on administration routes, Prisys offers an array of advanced drug delivery technologies optimized for respiratory therapy:
- Inhalation Delivery: A non-invasive, patient-friendly method targeting the lungs directly.
- Intra-bronchial Administration: Delivers therapeutics precisely to bronchial regions, maximizing local efficacy while minimizing systemic exposure.
- Intratracheal Administration: Facilitates rapid and localized delivery during emergency scenarios or intensive care interventions.
- The backbone of these methods is the Aerogen nebulization system, a state-of-the-art device ensuring high-efficiency aerosol delivery for consistent dosing across experiments.
- Moreover, Prisys is actively developing an N2B (Nose-to-Brain) platform aimed at enhancing central nervous system drug delivery.
Integrated Pulmonary Research Capabilities: One-Stop Scientific Support
Prisys's respiratory research platform integrates top-tier technologies and methodologies to offer full-cycle research support:
- NHP Biosafety Facility: Equipped with a specialized respiratory laboratory for high-containment studies.
- Clinical Imaging: CT imaging enables fibrosis assessment in IPF models, lung volume analysis, and pulmonary artery CTA.
- Lung Function Testing: Includes PC50 testing, FVC, and airway resistance evaluations.
- BALF Analysis: Quantitative measurements of inflammatory markers and cellular components, crucial for acute lung injury models.
- Histopathology: Comprehensive assessments via H&E, PAS, and immunohistochemistry (IHC) staining.
- In Vitro Assays: Flow cytometry, coagulation analysis, and collaborative services such as LC-MS, ELISA, and ELISpot.
Prisys's team ensures meticulous project design, laboratory execution, data analysis, and scientific publication support.
Conclusion: Partner with Prisys to Accelerate Respiratory Therapeutics
Driven by innovation, precision, and scientific excellence, Prisys is a trusted partner for pharmaceutical companies and research institutions advancing therapies for respiratory diseases. Its comprehensive non-human primate models, cutting-edge drug delivery systems, and end-to-end experimental capabilities form a solid foundation for impactful preclinical studies.
Whether you're exploring COPD, asthma, pulmonary fibrosis, or acute lung injury, Prisys delivers the tools, expertise, and infrastructure needed to bring respiratory therapies closer to the clinic.
